Fulgent Genetics (FLGT) Receivables (2015 - 2026)

Fulgent Genetics has reported Receivables for 12 years, with the latest figure at $66.4 million in Q2 2026.

• Quarterly Receivables fell 16.21% year-over-year to $66.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $66.4 million (down 16.21% YoY) and the FY2025 annual result came in at $85.9 million, up 21.34% from the prior year.
• Receivables declined to $66.4 million in Q2 2026 per FLGT's latest filing, from $70.4 million in the prior quarter.
• Over five years, Receivables peaked at $161.8 million in Q1 2022 and troughed at $35.7 million in Q2 2023.
• A 5-year average of $74.8 million and a median of $70.6 million in 2024 frame the typical range for Receivables.
• The sharpest annual moves came in 2023 and 2024: Receivables slumped 73.47% in 2023, then soared 61.81% in 2024.
• Over 5 years, Receivables stood at $72.6 million in 2022, then dropped by 27.74% to $52.5 million in 2023, then jumped by 34.96% to $70.8 million in 2024, then advanced by 21.34% to $85.9 million in 2025, then declined by 22.7% to $66.4 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $66.4 million, $70.4 million, and $85.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.